Limosilactobacillus oris

(aka Lactobacillus oris)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Limosilactobacillus oris, (aka Lactobacillus oris), is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 9 gut microbiome compilation studies or metastudies. The DNA G+C content is 49–51%. Limosilactobacillus oris is probably a common, although minor, coloniser of the gut. (Hammes2011fBergey; Rossi2016; Farrow1988)



  • This organism has been recovered from human faeces, and saliva. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. Likely to be transient and not a long-term gut commensal.
    • QUIRKS
  • Found in human breast milk (Jeurink2013).
    • GENERAL CHARACTERISTICS (Hammes2011fBergey); (Farrow1988);
    Character Response
  • ±
  • Strain-dependent hydrolysis or digestion:
  • aesculin; hippurate;
  • 🧂
  • Salt tolerance:
  • tolerates 4% salt;
  • 🌡
  • Temperature tolerance:
  • grows at 30℃; grows at 40℃; doesn't grow at 48℃;
  • H+
  • Acid from carbohydrates usually produced:
  • arabinose; L-arabinose; fructose; galactose; glucose; ribose; xylose; amygdalin; gentiobiose; lactose; maltose; melibiose; raffinose; sucrose; D-arabitol; gluconate;
  • ±
  • Strain-dependent acid from carbs:
  • mannose; cellubiose; trehalose;
  • ⥅
  • Substrates assimilated or utilised:
  • melibiose;
  • ±
  • Strain-dependent active enzymes:
  • urease;
    • SPECIAL FEATURES (Hammes2011fBergey); (Farrow1988);
    Character Response
  • ✗
  • Metabolites not produced:
  • H₂S; indole;
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2013); (Goldstein2013a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; imipenem; penicillin; penicillin G; piperacillin-tazobactam;
  • Macrolides:
  • erythromycin; quinupristin-dalfopristin;
  • Quinolines:
  • moxifloxacin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin;

  • Reuter, G. (2001). The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Current Issues in Intestinal Microbiology, 2(2), 43–53.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Bacilli Order:  Lactobacillales Family:  Lactobacillaceae Genus:  Limosilactobacillus Alt. name:  Lactobacillus oris Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  human faeces, and saliva
    DNA G+C(%):  49–51
    Lower T(℃):  30(+)
    Mid T(℃):  40(+)
    High T(℃):  48(neg)
    NaCl 3-5%:  4(+)
    		Aesculin:  d Gelatin:  neg Casein:  neg Hippurate:  d
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  + D-Arabinose:  neg L-Arabinose:  + Fructose:  + Fucose:  neg D-Fucose:  neg Galactose:  + Glucose:  + Mannose:  d D-Lyxose:  neg Rhamnose:  neg Ribose:  + Sorbose:  neg D-Tagatose:  neg Xylose:  + L-Xylose:  neg Cellubiose:  d Gentiobiose:  + Lactose:  + Maltose:  + Melezitose:  neg Melibiose:  + Sucrose:  + Trehalose:  d Turanose:  neg Amygdalin:  + Glycogen:  neg Inulin:  neg Starch:  neg Adonitol:  neg D-Arabitol:  + L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg Xylitol:  neg Arbutin:  neg Gluconate:  + 2-Ketogluconate:  neg 5-Ketogluconate:  neg Me-α-D-Glc:  neg Me-α-D-Mann:  neg Me-Xyloside:  neg NAc-α-GA:  neg Salicin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg Urease:  d ArgDH:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  neg Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.015-2)
    penicillin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.03-1)
    penicillin_G:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.03-1)
    piper-taz:  S(MIC50): 0.5, MIC90: 2, RNG: (0.02-8)
    imipenem:  S(MIC50): 0.125, MIC90: 2, RNG: (≤0.015-8)
    cefalexin:  Var(MIC50): 1, MIC90: >32, RNG: (0.25->32)
    azithromycin:  Var(MIC50): 0.06, MIC90: 8, RNG: (≤0.03->32)
    erythromycin:  S(MIC50): ≤0.03, MIC90: 2, RNG: (≤0.03-16)
    fidaxomicin:  Var(MIC50): 8, MIC90: >512, RNG: (0.25->512)
    quin-dalf:  S(MIC50): 0.5, MIC90: 2, RNG: (0.125-2)
    linezolid:  Var(MIC50): 4, MIC90: 8, RNG: (0.5-8)
    ciprofloxacin:  Var(MIC50): 1, MIC90: >8, RNG: (≤0.5->8)
    levofloxacin:  Var(MIC50): 0.5, MIC90: 8, RNG: (0.25-8)
    moxifloxacin:  S(MIC50): 0.5, MIC90: 8, RNG: (0.25–16)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tetracycline:  Var(MIC50): 1, MIC90: 16, RNG: (0.125-32)
    dalbavancin:  Var(MIC50): >0.5, MIC90: >32, RNG: (0.06->32)
    vancomycin:  R(MIC50): 256, MIC90: >512, RNG: (0.5->512)
    metronidazole:  R(MIC50): 32, MIC90: >32, RNG: (0.125->32)
    clindamycin:  S(MIC50): ≤0.03, MIC90: 0.5, RNG: (≤0.03->32)
    daptomycin:  Var(MIC50): >2, MIC90: >32, RNG: (0.25->32)

    References

    SPECIFIC REFERENCES FOR LIMOSILACTOBACILLUS ORIS
  • Zheng2020 - A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae.
  • Hammes2011fBergey - Bergey's manual of systematic bacteriology. Vol. 3, The Firmicutes. Family Lactobacillaceae, Genus I. Limosilactobacillus
  • Rossi2016 - Mining metagenomic whole genome sequences revealed subdominant but constant Lactobacillus population in the human gut microbiota.
  • Zhu2020 - Metagenome-wide association of gut microbiome features for schizophrenia
  • Goldstein2013 - In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
  • Goldstein2013a - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
  • Farrow1988 - Notes: Lactobacillus oris sp. nov. from the Human Oral Cavity.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR LIMOSILACTOBACILLUS ORIS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • MacFarlane2004 - Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Woodmansey2004 - Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR LIMOSILACTOBACILLUS ORIS
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021